Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A phase II study of mitoxantrone.

G Cartei1, S Mian, R Cendron

  • 1Division of Oncology, Ospedale S. Maria Misericordia, Udine, Italia.

Tumori
|October 31, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of workload generated in the two years following first consultation by each new cancer patient: studying the past to plan the future of cancer care.

BMC health services research·2022
Same author

Transformation of Cancer Care during and after the COVID Pandemic, a point of no return. The Experience of Italy.

Journal of cancer policy·2021
Same author

Nanoscale optical writing through upconversion resonance energy transfer.

Science advances·2021
Same author

What to do in an oncology department to face the new COVID-19 era challenges?

Medical oncology (Northwood, London, England)·2020
Same author

Testing commercial biopreservative against spoilage microorganisms in MAP packed Ricotta fresca cheese.

Food microbiology·2017
Same author

Striated muscle activator of Rho signalling (STARS) is reduced in ageing human skeletal muscle and targeted by miR-628-5p.

Acta physiologica (Oxford, England)·2016

Mitoxantrone demonstrated acceptable tolerability in heavily pretreated patients with solid tumors or myeloproliferative diseases. The drug showed some effectiveness, including stable disease, even as a later line of therapy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Patients with advanced solid tumors or myeloproliferative diseases often have limited treatment options.
  • Evaluating novel therapeutic strategies in heavily pretreated populations is crucial for improving patient outcomes.

Purpose of the Study:

  • To assess the safety and efficacy of mitoxantrone in pretreated patients with progressive solid tumors or myeloproliferative diseases.
  • To determine the tolerability of mitoxantrone when administered at a specific dose and schedule in this patient cohort.

Main Methods:

  • Thirty pretreated patients received mitoxantrone (5 mg/m2/day for 3 consecutive days every 3 weeks).
  • Patients had progressive solid tumors (24) or myeloproliferative diseases (6).
  • Response and toxicity were evaluated over 104 administered cycles.

Related Experiment Videos

Main Results:

  • Mitoxantrone was generally well tolerated, with myelodepression being the most common reason for cycle delay.
  • Alopecia (Grade I-II) occurred in 16 patients; chronic cardiac toxicity was observed in one patient.
  • Among 25 evaluable patients, one achieved a partial response (PR), one had a minor response (MR), and eleven had stable disease.

Conclusions:

  • Mitoxantrone, at the studied dose and schedule, is a tolerable option for heavily pretreated patients with advanced cancers.
  • The observed efficacy, including disease stabilization, is significant given mitoxantrone's position as a later-line treatment.